Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FHTX
stocks logo

FHTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.76M
+276.84%
-0.286
-4.76%
6.65M
+11.67%
-0.320
+6.67%
6.70M
-11.36%
-0.333
+19.05%
Estimates Revision
The market is revising Upward the revenue expectations for Foghorn Therapeutics Inc. (FHTX) for FY2025, with the revenue forecasts being adjusted by 2.44% over the past three months. During the same period, the stock price has changed by -20.62%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.11%
In Past 3 Month
Stock Price
Go Down
down Image
-20.62%
In Past 3 Month
Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 10.80 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 10.80 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.580
sliders
Low
9.00
Averages
10.80
High
13.00
Current: 4.580
sliders
Low
9.00
Averages
10.80
High
13.00
Stifel
initiated
$12
2025-12-03
New
Reason
Stifel
Price Target
$12
2025-12-03
New
initiated
Reason
Stifel initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target. Lead asset FHD-909, partnered 50/50 with Eli Lilly (LLY), expects initial data in 2026, notes the analyst, who models a 2030 launch and about $1.4B in global peak sales, including about $500M to Foghorn. The company's cash runway extends into 2028, well past initial FHD-909 proof-of-concept data and likely the first degrader data set, the analyst tells investors.
Guggenheim
NULL
to
Buy
initiated
$12
2025-11-07
Reason
Guggenheim
Price Target
$12
2025-11-07
initiated
NULL
to
Buy
Reason
Guggenheim initiated coverage of Foghorn Therapeutics with a Buy rating and $12 price target.
B. Riley
Yuan Zhi
Buy
maintain
$10
2025-09-17
Reason
B. Riley
Yuan Zhi
Price Target
$10
2025-09-17
maintain
Buy
Reason
B. Riley analyst Yuan Zhi kept a Buy rating on Foghorn Therapeutics with a $10 price target following a transfer of coverage. Foghorn is a clinical-stage biotech company developing targeted oncology therapies that modulate the chromatin regulatory system, the analyst tells investors in a research note. The firm believes investors are ignoring FHD-909's upside potential and anticipates sequential positive reactions following PRT7732's and FHD-909's clinical readouts in late 2025 and early 2026E, respectively.
JMP Securities
Silvan Tuerkcan
Buy
Initiates
$9
2025-04-23
Reason
JMP Securities
Silvan Tuerkcan
Price Target
$9
2025-04-23
Initiates
Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$13
2025-03-07
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$13
2025-03-07
Reiterates
Strong Buy
Reason
B. Riley Securities
Kalpit Patel
Strong Buy
Initiates
$10
2025-01-30
Reason
B. Riley Securities
Kalpit Patel
Price Target
$10
2025-01-30
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Foghorn Therapeutics Inc (FHTX.O) is -3.75, compared to its 5-year average forward P/E of -4.46. For a more detailed relative valuation and DCF analysis to assess Foghorn Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.46
Current PE
-3.75
Overvalued PE
-2.58
Undervalued PE
-6.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.84
Undervalued EV/EBITDA
-4.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
75.96
Current PS
0.00
Overvalued PS
251.37
Undervalued PS
-99.44
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FHTX News & Events

Events Timeline

(ET)
2025-11-05
07:02:15
Foghorn Therapeutics announces Q3 earnings per share of 25 cents, below consensus estimate of 30 cents.
select
2025-10-30 (ET)
2025-10-30
07:37:19
Foghorn Reveals New Developments for Selective ARID1B, Selective CBP, and Selective EP300
select
2025-10-16 (ET)
2025-10-16
07:08:26
Foghorn Therapeutics Reports Advancements in Selective ARID1B Degrader Initiative
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-04Yahoo Finance
Stifel Nicolaus Begins Coverage of Foghorn Therapeutics, Assigns Buy Rating and $12 Price Target
  • Company Overview: Foghorn Therapeutics (FHTX) is currently rated as a Buy by analysts.
  • Price Target: The mean price target for FHTX is set at $11.43.
[object Object]
Preview
6.0
11-08Benzinga
Aardvark Therapeutics Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday

  • Analyst Coverage Initiations: BTIG analyst Jeet Mukherjee initiated coverage on Aardvark Therapeutics, Inc. with a Buy rating and a price target of $26, while UBS analyst Timothy Arcuri gave Impinj, Inc. a Neutral rating with a price target of $200.

  • Foghorn Therapeutics Rating: Guggenheim analyst Michael Schmidt initiated coverage on Foghorn Therapeutics Inc. with a Buy rating and a price target of $12.

  • Current Stock Prices: Aardvark Therapeutics shares closed at $9.87, Foghorn Therapeutics at $4.00, and Impinj at $169.06 as of Thursday.

  • Market Insights: The article highlights the importance of analyst ratings in guiding investment decisions, with a link to a comprehensive analyst ratings page for further insights.

[object Object]
Preview
1.0
11-03Newsfilter
Foghorn Therapeutics Set to Attend Three Upcoming Investor Conferences

  • Company Overview: Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines that correct abnormal gene expression, particularly in oncology, through its Gene Traffic Control® platform.

  • Upcoming Conferences: The company will participate in three major healthcare conferences: Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference, with presentations by CEO Adrian Gottschalk.

  • Presentation Details: Foghorn's management will engage in fireside chats and one-on-one meetings at these conferences, providing insights into their innovative approaches and pipeline.

  • Webcast Availability: Presentations from the conferences will be accessible via the company's website under "Events & Presentations" for 90 days following the events.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Foghorn Therapeutics Inc (FHTX) stock price today?

The current price of FHTX is 4.58 USD — it has increased 3.15 % in the last trading day.

arrow icon

What is Foghorn Therapeutics Inc (FHTX)'s business?

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

arrow icon

What is the price predicton of FHTX Stock?

Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 10.80 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Foghorn Therapeutics Inc (FHTX)'s revenue for the last quarter?

Foghorn Therapeutics Inc revenue for the last quarter amounts to 8.15M USD, increased 4.42 % YoY.

arrow icon

What is Foghorn Therapeutics Inc (FHTX)'s earnings per share (EPS) for the last quarter?

Foghorn Therapeutics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -19.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Foghorn Therapeutics Inc (FHTX)'s fundamentals?

The market is revising Upward the revenue expectations for Foghorn Therapeutics Inc. (FHTX) for FY2025, with the revenue forecasts being adjusted by 2.44% over the past three months. During the same period, the stock price has changed by -20.62%.
arrow icon

How many employees does Foghorn Therapeutics Inc (FHTX). have?

Foghorn Therapeutics Inc (FHTX) has 112 emplpoyees as of December 05 2025.

arrow icon

What is Foghorn Therapeutics Inc (FHTX) market cap?

Today FHTX has the market capitalization of 259.00M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free